Chronic cough in post-COVID syndrome: Laryngeal electromyography findings in vagus nerve neuropathy.

BACKGROUND: Despite being a new entity, there is a large amount of information on the characteristics of SARS-CoV-2 infection and the symptoms of the acute phase; however, there are still many unknowns about the clinical features and pathophysiology of post-COVID syndrome. Refractory chronic cough is one of the most prevalent symptoms and carries both a medical problem and a social stigma. Many recent studies have highlighted the role of SARS-CoV-2 neurotropism, but no studies have demonstrated vagus nerve neuropathy as a cause of persistent chronic cough or other COVID-19 long-term effects. OBJECTIVE: The main objective was to assess the involvement of the vagus nerve neuropathy as a cause of chronic cough and other post-COVID syndrome symptoms. MATERIAL AND METHODS: This was a single-center observational study with prospective clinical data collected from 38 patients with chronic cough and post-COVID-19 syndrome. Clinical characteristics and laryngeal electromyographic findings were analyzed. RESULTS: Clinical data from 38 patients with chronic cough after 12 weeks of the acute phase of COVID-19 infection were analyzed. Of these patients, 81.6% suffered from other post-COVID conditions and, 73.6% reported fluctuating evolution of symptoms. Laryngeal electromyography (LEMG) of the thyroarytenoid (TA) muscles and cricothyroid (CT) muscles was pathological in 76.3% of the patients. Of the patients with abnormal LEMG, chronic denervation was the most frequent finding (82.8%), 10.3% presented acute denervation signs, and 6.9% presented myopathic pattern in LEMG. CONCLUSIONS: LEMG studies suggest the existence of postviral vagus nerve neuropathy after SARS-CoV-2 infection that could explain chronic cough in post-COVID syndrome.

Audiological evaluation (128-20,000Hz) in women with autoimmune thyroiditis: The role of antibodies vs. l-thyroxine deficiency.

BACKGROUND AND AIM: Although sensorineural hearing loss may have different aetiologies, we focused on autoimmune hearing loss since it may be reversible with corticosteroid therapy; this entity is sometimes associated with systemic autoimmune diseases. Hashimoto's thyroiditis or chronic autoimmune thyroiditis shows antibodies and may be harmful to hearing thresholds regardless of hypothyroidism effect. To date this effect has not been sufficiently studied and never with extended high frequencies. The aim of this work is to study by age groups whether hearing thresholds in the human auditory range (128-20,000Hz) are affected in Hashimoto's disease. MATERIALS AND METHODS: Two groups of 128 patients affected by Hashimoto's thyroiditis were included. First group: patients with pathological antithyroid antibodies who do not need L-thyroxine treatment. Second group: patients controlled with L-thyroxine substitutive treatment. Audiometric threshold study comparing between the groups of patients and a group of 209 controls was performed. All patients underwent complete otorhinolaryngological examination, antithyroid antibodies, TSH, T3 and T4 blood levels, tympanometry, conventional pure-tone audiometry, and extended-high-frequency audiometry. RESULTS: All patients were women. Both groups showed worst audiometric thresholds than the control group; both study groups showed worse hearing than controls, this difference was statistically significant in all frequencies. In the 8-20kHz frequency range, this difference was more than 10dB, and in the 9-16kHz and 20kHz range this difference was more than 20dB. When separated by age groups, in younger subjects (20-29 years) these differences were found in all frequencies, except for conversational frequencies (500-4,000Hz); between 30 and 49 years the difference is statistically significant in all frequencies; and from 50 to 69 years differences are found, especially in the conversational frequencies. CONCLUSIONS: This first work studying the human auditory range in the chronic autoimmune thyroiditis or Hashimoto's thyroiditis confirms that hearing loss related to the autoimmune disorder predominates at extended-high-frequencies initially. But ends up involving all frequencies in pure-tone conventional audiometry, then it may be detected in routine clinical tests. These results support the role of extended-high-frequencies audiometry to diagnose subclinical hearing loss in patients affected by Hashimoto's thyroiditis.

Estudio de la audición (128-20.000 Hz) en mujeres con tiroiditis autoinmune: papel de los anticuerpos frente al déficit de hormona tiroidea / Audiological evaluation (128-20.000 Hz) in women with autoinmune thyroiditis: The role of antibodies vs. l-thyroxine deficiency

Antecedentes y objetivo: Hay muchas causas de hipoacusia neurosensorial, entre las que tiene especial interés la patología autoinmune del oído interno por su posible reversibilidad con tratamiento esteroideo, a veces asociada a enfermedades sistémicas autoinmunes. La tiroiditis crónica autoinmune o de Hashimoto (TA) presenta anticuerpos que podrían afectar al oído interno independientemente del hipotiroidismo, efecto que no ha sido suficientemente estudiado y nunca mediante audiometría con extensión en altas frecuencias.El objetivo de este trabajo es estudiar si existe afectación de los umbrales auditivos en pacientes de TA, sin hipotiroidismo, en la totalidad del espectro auditivo humano (128 Hz – 20 kHz) distribuido por grupos de edad.Materiales y métodosSe han seleccionado 128 pacientes divididos en dos grupos. El primer grupo de pacientes presenta anticuerpos antitiroideos elevados sin necesitar tratamiento sustitutivo con tiroxina. El segundo grupo con tratamiento sustitutivo con tiroxina, bien controlados. Se comparan con el grupo control (GC) de 209 pacientes. En todos se realizó historia clínica, exploración otológica, estudio de niveles de anticuerpos antitiroideos, TSH (thyroid-stimulating hormone), T3 y T4 libres, timpanograma, estudio audiométrico convencional y con extensión en altas frecuencias.ResultadosTodos los pacientes fueron mujeres. Ambos grupos mostraron peor audición que los controles, siendo la diferencia estadísticamente significativa en todas las frecuencias; en el rango de frecuencias de 8 – 20 kHz con una diferencia de más de 10 dB, y en los rangos de 9-16 kHz y de 20 kHz de más de 20 dB. (AU)

Background and aim: Although sensorineural hearing loss may have different aetiologies, we focused on autoimmune hearing loss since it may be reversible with corticosteroid therapy; this entity is sometimes associated with systemic autoimmune diseases. Hashimoto's thyroiditis or chronic autoimmune thyroiditis shows antibodies and may be harmful to hearing thresholds regardless of hypothyroidism effect. To date this effect has not been sufficiently studied and never with extended high frequencies. The aim of this work is to study by age groups whether hearing thresholds in the human auditory range (128 to 20.000 Hz) are affected in Hashimoto's disease.Materials and methodsTwo groups of 128 patients affected by Hashimoto's thyroiditis were included. First group: patients with pathological antithyroid antibodies who do not need L-thyroxine treatment. Second group: patients controlled with L-thyroxine substitutive treatment. Audiometric threshold study comparing between the groups of patients and a group of 209 controls was performed. All patients underwent complete otorhinolaryngological examination, antithyroid antibodies, TSH, T3 and T4 blood levels, tympanometry, conventional pure-tone audiometry, and extended-high-frequency audiometry.ResultsAll patients were women. Both groups showed worst audiometric thresholds than the control group; both study groups showed worse hearing than controls, this difference was statistically significant in all frequencies. In the 8-20 kHz frequency range this difference was more than 10 dB, and in the 9-16 kHz and 20 kHz range this difference was more than 20 dB. When separated by age groups, in younger subjects (20-29 years) these differences were found in all frequencies, except for conversational frequencies (500 - 4,000 Hz); between 30 and 49 years the difference is statistically significant in all frequencies; and from 50 to 69 years differences are found, especially in the conversational frequencies. (AU)

Prevalence of presbycusis in an otologically normal population / Prevalencia de presbiacusia en una población otológicamente norma

OBJECTIVE: Presbycusis or age-related hearing loss is a bilaterally symmetric sensorineural hearing loss associated exclusively with age, excluding any other causes of hearing loss. Presbycusis is very relevant because of its high prevalence, and its consequences (e.g., alterations in communication, social isolation, depression, dementia), and the economic impact. This paper reports the first attempt to estimate the prevalence of presbycusis in an otologically normal population, i.e., without previous ear disease, exposure to noise, or potentially ototoxic substances, or familial hearing loss. METHODS: A total of 4290 subjects from 5 to 90 years old were included in the study. RESULTS: No statistically significant differences were found between right and left ear, nor between males and females, in any of the age groups. Presbycusis was detected over 60 years following the WHO classification; although the results vary depending on the classification used. Moderate hearing loss (≥ 41 dB) was detected in the population over 72 years. None of the subjects had severe or profound hearing impairment. The prevalence of presbycusis increased with age, being 100% in individuals aged 80 years and older. The prevalence of presbycusis is highly variable depending on the pure-tone averaged frequencies and the classification system used; therefore, a common classification system should be used. CONCLUSIONS: An otologically normal population is needed to establish the prevalence of presbycusis as in non-screened populations it is the hearing level including all types of hearing loss that is measured, but not presbycusis itself

ANTECEDENTES Y OBJETIVO: La presbiacusia o pérdida auditiva relacionada con la edad, es una hipoacusia neurosensorial bilateral y simétrica asociada exclusivamente a la edad. La presbiacusia es muy relevante debido a su alta prevalencia y sus consecuencias (alteraciones en la comunicación, aislamiento social, depresión, demencia) y el impacto económico. Este es el primer trabajo que aporta datos sobre la prevalencia de la presbiacusia en una población otológicamente normal, es decir, sin enfermedad auditiva previa, exposición a ruido o sustancias potencialmente ototóxicas o pérdida de audición familiar. MATERIAL Y MÉTODOS: Un total de 4.290 sujetos de 5 a 90 años de edad fueron incluidos en el estudio. RESULTADOS: No se encontraron diferencias entre el oído derecho y el izquierdo, ni entre varones y mujeres. La presbiacusia se detectó a partir de los 60 años siguiendo la clasificación de la OMS, aunque los resultados varían dependiendo de la clasificación utilizada. Se detectó hipoacusia moderada (≥ 41dB) en la población mayor de 72 años. Ninguno de los sujetos tenía hipoacusia grave o profunda. La prevalencia de presbiacusia aumentó con la edad, siendo del 100% en individuos de 80 años o más. La prevalencia de la presbiacusia es altamente variable dependiendo de las frecuencias promediadas y del sistema de clasificación utilizado; por lo tanto, debería utilizarse un sistema de clasificación común. CONCLUSIONES: Para establecer la prevalencia de la presbiacusia se necesita una población otológicamente normal ya que, si la población no está cribada, lo que se mide es la hipoacusia que incluye todos los tipos de pérdida auditiva, pero no la presbiacusia de forma aislada

Prevalence of presbycusis in an otologically normal population.

OBJECTIVE: Presbycusis or age-related hearing loss is a bilaterally symmetric sensorineural hearing loss associated exclusively with age, excluding any other causes of hearing loss. Presbycusis is very relevant because of its high prevalence, and its consequences (e.g., alterations in communication, social isolation, depression, dementia), and the economic impact. This paper reports the first attempt to estimate the prevalence of presbycusis in an otologically normal population, i.e., without previous ear disease, exposure to noise, or potentially ototoxic substances, or familial hearing loss. METHODS: A total of 4290 subjects from 5 to 90 years old were included in the study. RESULTS: No statistically significant differences were found between right and left ear, nor between males and females, in any of the age groups. Presbycusis was detected over 60 years following the WHO classification; although the results vary depending on the classification used. Moderate hearing loss (≥ 41dB) was detected in the population over 72 years. None of the subjects had severe or profound hearing impairment. The prevalence of presbycusis increased with age, being 100% in individuals aged 80 years and older. The prevalence of presbycusis is highly variable depending on the pure-tone averaged frequencies and the classification system used; therefore, a common classification system should be used. CONCLUSIONS: An otologically normal population is needed to establish the prevalence of presbycusis as in non-screened populations it is the hearing level including all types of hearing loss that is measured, but not presbycusis itself.

l-Thyroxine does not prevent immunemediated sensorineural hearing loss in autoimmune thyroid diseases / l-Tiroxina no previene la hipoacusia neurosensorial inmuno-mediada en enfermedades tiroideas autoinmunes

Objective: This is the first report dealing with immune-mediated inner ear disease (IMIED) hearing loss in a group of patients affected with autoimmune thyroid disease (AITD), whose treatment required corticosteroids, despite being treated with levothyroxine. Immunopathology linking the inner ear and the thyroid gland is also presented. Patients: A total of 220 patients were selected with sensorineural hearing loss (SNHL) of causes other than presbycusis. Audiometry was performed and pure tone average was calculated before and after treatment with corticosteroids. Results: Eighty-four (84) patients had SNHL of autoimmune origin, and 15 patients were diagnosed with AITD (Hashimoto's disease). Bilateral hearing loss was observed in 10 patients (66.5%). Sudden sensorineural hearing loss was the most frequent clinical form of presentation. Nine patients showed a hearing recovery greater than 10 dB after corticosteroid treatment. Conclusions: Acquired hypothyroidism is thought to affect hearing due to different mechanisms. Although specific hormonal therapy may improve peripheral or central auditory disorders associated with hypothyroidism, the presence of IMIED in AITD patients requires another approach. Altered immune regulatory mechanisms involving Treg cells and CD4+CD45RO cells have been suggested in patients with AITD and IMIED. In the present study, although all the patients with hypothyroidism and subclinical hypothyroidism were being treated with levothyroxine, immune-mediated hearing loss was observed. Therapy with corticosteroids could achieve hearing recovery. Since inner ear and thyroid gland share possible antigen targets, we highlight the existence of IMIED in AITD patients and the importance of implementing appropriate therapy with corticosteroids

Objetivo: Este es el primer trabajo que trata la hipoacusia por enfermedad inmune-mediada del oído interno (IMIED) en un grupo de pacientes afectados de tiroiditis autoinmune (AITD), cuyo tratamiento requirió corticosteroides, a pesar de haber sido tratados con levotiroxina. También se presenta la inmunopatología que vincula el oído interno y la glándula tiroides. Pacientes: Se seleccionó un total de 220 pacientes con hipoacusia neurosensorial (SNHL) por causas diferentes a presbiacusia. A todos los pacientes se les realizó una audiometría, calculándose la media de tonos puros antes y después del tratamiento con corticosteroides. Resultados: Ochenta y cuatro (84) pacientes tenían SNHL de origen autoinmune, y 15 pacientes fueron diagnosticados de AITD (Enfermedad de Hashimoto). Se observó hipoacusia bilateral en 10 pacientes (66,5%). La sordera súbita fue la forma de presentación clínica más frecuente. Nueve pacientes presentaron una recuperación auditiva superior a 10 dB tras el tratamiento con corticosteroides. Conclusiones: Se piensa que el hipotiroidismo adquirido afecta a la audición por diferentes mecanismos. Aunque la terapia hormonal específica puede mejorar los trastornos auditivos periféricos o centrales asociados al hipotiroidismo, la presencia de IMIED en los pacientes de AITD requiere otro abordaje. Se ha sugerido una alteración de los mecanismos reguladores de la respuesta inmune que implica a las células de Treg y a las células CD4+CD45RO en los pacientes con AITD e IMIED. En el presente estudio, a pesar de que todos los pacientes con hipotiroidismo e hipotiroidismo subclínico estaban siendo tratados con levotiroxina, se observó hipoacusia inmuno-mediada. La terapia con corticosteroides podría lograr una recuperación auditiva. Dado que el oído interno y la glándula tiroides comparten posibles antígenos diana, destacamos la existencia de IMIED en los pacientes de AITD, y la instauración de una terapia adecuada con corticosteroides

l-Thyroxine does not prevent immunemediated sensorineural hearing loss in autoimmune thyroid diseases.

OBJECTIVE: This is the first report dealing with immune-mediated inner ear disease (IMIED) hearing loss in a group of patients affected with autoimmune thyroid disease (AITD), whose treatment required corticosteroids, despite being treated with levothyroxine. Immunopathology linking the inner ear and the thyroid gland is also presented. PATIENTS: A total of 220 patients were selected with sensorineural hearing loss (SNHL) of causes other than presbycusis. Audiometry was performed and pure tone average was calculated before and after treatment with corticosteroids. RESULTS: Eighty-four (84) patients had SNHL of autoimmune origin, and 15 patients were diagnosed with AITD (Hashimoto's disease). Bilateral hearing loss was observed in 10 patients (66.5%). Sudden sensorineural hearing loss was the most frequent clinical form of presentation. Nine patients showed a hearing recovery greater than 10dB after corticosteroid treatment. CONCLUSIONS: Acquired hypothyroidism is thought to affect hearing due to different mechanisms. Although specific hormonal therapy may improve peripheral or central auditory disorders associated with hypothyroidism, the presence of IMIED in AITD patients requires another approach. Altered immune regulatory mechanisms involving Treg cells and CD4+CD45RO cells have been suggested in patients with AITD and IMIED. In the present study, although all the patients with hypothyroidism and subclinical hypothyroidism were being treated with levothyroxine, immune-mediated hearing loss was observed. Therapy with corticosteroids could achieve hearing recovery. Since inner ear and thyroid gland share possible antigen targets, we highlight the existence of IMIED in AITD patients and the importance of implementing appropriate therapy with corticosteroids.

Esofagitis eosinofílica: una entidad patológica relevante para el otorrinolaringólogo / Eosinophilic esophagitis: A relevant entity for the otolaryngologist

La esofagitis eosinofílica (EE) es una entidad clínico patológica reconocida recientemente y con una prevalencia que va en aumento desde su descripción inicial. Su diagnóstico representa un reto para diferentes especialistas, entre los que tiene un rol destacado el otorrinolaringólogo. La sospecha clínica ante un paciente que presenta episodios recidivantes de impactación de alimentos no punzantes o ante un niño con trastornos de la alimentación y antecedentes de atopia constituyen el primer signo de alerta de una posible EE. El objetivo de esta revisión persigue destacar el papel de la EE en el diagnóstico diferencial de los pacientes con trastornos de la deglución, así como dar a conocer las manifestaciones clínicas que deben alertar al otorrinolaringólogo para proseguir la realización de las pruebas encaminadas al diagnóstico de esta enfermedad. La esofagoscopia transnasal, realizada por el otorrinolaringólogo en consulta, ayudará a disminuir el número de casos infradiagnosticados. Dado que gran parte de los pacientes afectos de trastornos de la deglución van a ser evaluados por el otorrinolaringólogo, se hace imprescindible el reconocimiento de la EE, así como el manejo diagnóstico-terapéutico por un equipo multidisciplinar en el que se involucren, además del otorrinolaringólogo, pediatras, digestólogos, alergólogos y patólogos familiarizados con la enfermedad. La identificación del alimento responsable de la inflamación del esófago y su eliminación de la dieta es la clave del tratamiento de este desorden inmunomediado (AU)

Eosinophilic esophagitis (EE) is a recently recognised pathologic entity whose prevalence has risen significantly since it was first described. Its diagnosis represents a challenge for different medical specialties, among which ENT specialists play an important role. Clinical suspicion in a patient with recurrent food impaction or a child with eating disorders and history of hypersensitivity constitutes the first warning sign of a possible EE. The purpose of this review is to highlight EE as a possible differential diagnosis in patients with deglutition disorders and describe the possible clinical symptoms that should alert the ENT specialist to perform appropriate diagnostic tests and procedures. The transnasal esophagoscopy, performed in-office by the ENT, is ideal for reducing possible underdiagnosed cases. Given the fact that an ENT specialist will evaluate a great many patients with deglutition disorders, it is paramount for possible EE cases to be suspected and recognised so that a correct multidisciplinary approach involving not only ENT specialists but also paediatricians, gastroenterologists, allergologists and pathologists can be established. Identifying the dietary component responsible for the esophageal inflammation and removing that food from the patient's diet is the key in the treatment of this immune-mediated disease (AU)

Eosinophilic esophagitis: A relevant entity for the otolaryngologist. / Esofagitis eosinofílica: una entidad patológica relevante para el otorrinolaringólogo.

Eosinophilic esophagitis (EE) is a recently recognised pathologic entity whose prevalence has risen significantly since it was first described. Its diagnosis represents a challenge for different medical specialties, among which ENT specialists play an important role. Clinical suspicion in a patient with recurrent food impaction or a child with eating disorders and history of hypersensitivity constitutes the first warning sign of a possible EE. The purpose of this review is to highlight EE as a possible differential diagnosis in patients with deglutition disorders and describe the possible clinical symptoms that should alert the ENT specialist to perform appropriate diagnostic tests and procedures. The transnasal esophagoscopy, performed in-office by the ENT, is ideal for reducing possible underdiagnosed cases. Given the fact that an ENT specialist will evaluate a great many patients with deglutition disorders, it is paramount for possible EE cases to be suspected and recognised so that a correct multidisciplinary approach involving not only ENT specialists but also paediatricians, gastroenterologists, allergologists and pathologists can be established. Identifying the dietary component responsible for the esophageal inflammation and removing that food from the patient's diet is the key in the treatment of this immune-mediated disease.

Central pontine myelinolysis as a cause of bilateral vocal fold immobility due to hyponatremia.

We report a patient admitted with severe dyspnea due to bilateral vocal fold immobility (BVFI), associated with hyponatremia and pneumonia that required emergency tracheotomy. Cerebral magnetic resonance imaging showed a pons lesion compatible with central pontine myelinolysis. Hyponatremia is thought to be caused by hypovolemia. The hyponatremia, and not its correction, is speculated to be the cause of central pontine myelinolysis in this patient. To our knowledge, this is the first case reported of a bilateral vocal fold immobility caused by central pontine myelinolysis induced by hyponatremia.

Validación de la versión en español del índice de incapacidad vocal (S-VHI) para el canto / Validation of the Spanish version of the voice handicap index for vocal singing (SVHI)

En los cuestionarios que existen actualmente en español para valorar la repercusión en la calidad de vida de la patología de la voz no hay preguntas que hagan referencia específicamente a la voz cantada. Se exponen los resultados de la validación del índice de incapacidad vocal para voz cantada (S-VHI) en español. Material y métodos: Se tradujo al español la versión validada en inglés. El cuestionario fue contestado por 29 cantantes que aquejaban algún tipo de dificultad específica relacionada con la voz cantada y 81 cantantes sanos. Resultados: Se encontró una fiabilidad test-retest buena (r=0,63, p=0,000). Respecto a la correlación ítem-total se encontró que todos los ítems individuales muestran altas correlaciones. Se hallaron correlaciones significativas entre la severidad de la puntuación de la autovaloración de la voz hecha por el cantante y las puntuaciones totales del S-VHI (r=0,52, p=0,000). Se demostraron diferencias significativas entre el grupo de cantantes con disfonía y el grupo control en las puntuaciones del S-VHI (ANOVA, F=10,9, p< 0,002). Conclusiones: La versión traducida al español del cuestionario S-VHI es una herramienta validada, con una correcta consistencia interna y fiabilidad. La puntuación media del S-VHI en una población de cantantes sanos es de un 20% de la puntuación máxima posible del cuestionario, muy por encima de la puntuación media en una población sana para la voz hablada determinada con el VHI-30 (AU)

In the questionnaires that currently exist in Spanish to assess the impact on quality of life of voice pathology, there are no questions that refer specifically to the singing voice. We present the results of the validation of the Singing Voice Handicap Index (SVHI) in Spanish. Materials and methods: The SVHI was translated into Spanish from the validated version in English. The questionnaire was completed by 29 dysphonic singers and 81 healthy singers. Results: There was good test-retest reliability (r=0.63, p=0.000). Regarding the item-total correlation, it was found that all samples had high correlations on individual items. Significant correlations were found between the severity of the score of the voice self-rated by the singer and the total scores of the SVHI (r=0.52, p=0.000). There were significant differences between the group of singers with dysphonia and the control group in the SVHI scores (ANOVA, F=10.9, p <0.002). Conclusions: The Spanish version of the translated SVHI questionnaire is a validated tool with proper internal consistency and reliability. The average score of the SVHI singers in a healthy population is 20% of the maximum possible questionnaire score, well above the average score in a healthy population for the spoken voice with the 30-item specific VHI (AU)

[Validation of the Spanish version of the voice handicap index for vocal singing (SVHI)]. / Validación de la versión en español del índice de incapacidad vocal (S-VHI) para el canto.

UNLABELLED: In the questionnaires that currently exist in Spanish to assess the impact on quality of life of voice pathology, there are no questions that refer specifically to the singing voice. We present the results of the validation of the Singing Voice Handicap Index (SVHI) in Spanish. MATERIALS AND METHODS: The SVHI was translated into Spanish from the validated version in English. The questionnaire was completed by 29 dysphonic singers and 81 healthy singers. RESULTS: There was good test-retest reliability (r=0.63, p=0.000). Regarding the item-total correlation, it was found that all samples had high correlations on individual items. Significant correlations were found between the severity of the score of the voice self-rated by the singer and the total scores of the SVHI (r=0.52, p=0.000). There were significant differences between the group of singers with dysphonia and the control group in the SVHI scores (ANOVA, F=10.9, p <0.002). CONCLUSIONS: The Spanish version of the translated SVHI questionnaire is a validated tool with proper internal consistency and reliability. The average score of the SVHI singers in a healthy population is 20% of the maximum possible questionnaire score, well above the average score in a healthy population for the spoken voice with the 30-item specific VHI.

Voice quality after endoscopic laser surgery and radiotherapy for early glottic cancer: objective measurements emphasizing the Voice Handicap Index.

We analyzed the functional outcome and self-evaluation of the voice of patients with T1 glottic carcinoma treated with endoscopic laser surgery and radiotherapy. We performed an objective voice evaluation, as well as a physical, emotional and functional well being assessment of 19 patients treated with laser surgery and 18 patients treated with radiotherapy. Voice quality is affected both by surgery and radiotherapy. Voice parameters only show differences in the maximum phonation time between both treatments. Results in the Voice Handicap Index show that radiotherapy has less effect on patient voice quality perception. There is a reduced impact on the patient's perception of voice quality after radiotherapy, despite there being no significant differences in vocal quality between radiotherapy and laser cordectomy.

[Adaptation and validation to the Spanish of the Voice Handicap Index (VHI-30) and its shortened version (VHI-10)]. / Adaptación y validación del índice de incapacidad vocal (VHI-30) y su versión abreviada (VHI-10) al español.

INTRODUCTION: The Voice Handicap Index has been shown to be a valid instrument for assessing self-perceived handicap associated with dysphonia. OBJECTIVES: To test the psychometric properties of the Spanish version of the VHI-30 (Voice Handicap Index) and its shortened version VHI-10. SUBJECTS AND METHOD: The original VHI-30 was translated into Spanish and was completed by 232 dysphonic patients and 38 non-dysphonic individuals. Prospective instrument validation was performed. RESULTS: Results showed high test-retest reliability, and high item-total correlation for both Spanish VHI-30 and VHI-10. Internal consistency demonstrated a Cronbach's alpha of 0.93 and 0.86, respectively, and a significant correlation was found between the VHI scores and the patients' self-rated dysphonic severity. CONCLUSIONS: The present study supports the use of Spanish versions of VHI-30 and VHI-10 because of their validity and reliability.

Adaptación y validación del índice de incapacidad vocal (VHI-30) y su versión abreviada (VHI-10) al español / Adaptation and Validation to the Spanish of the Voice Handicap Index (VHI-30) and its Shortened Version (VHI-10)

Introducción y objetivos: El índice de incapacidad vocal (Voice Handicap Index) es un instrumento válido para la valoración del menoscabo asociado a la disfonía que percibe el paciente. El objetivo es valorar las propiedades psicométricas de la versión castellana del VHI-30 y su versión abreviada VHI-10. Sujetos y método: El VHI-30 original se tradujo al idioma español y lo contestaron 232 pacientes con disfonía y 38 sujetos sanos. Se realizó una validación prospectiva del instrumento. Resultados: Se encuentra una alta fiabilidad test-retest y altas correlaciones ítem-total tanto para el VHI-30 como para el VHI-10. La coherencia interna demuestra valores alfa de Cronbach de 0,93 y 0,86 respectivamente, y se encontró una correlación significativa entre las puntuaciones del VHI y la valoración de los pacientes de la severidad de su disfonía. Conclusiones: El presente estudio apoya el uso de las versiones en español del VHI-30 y del VHI-10 por su validez y fiabilidad

Introduction: The Voice Handicap Index has been shown to be a valid instrument for assessing self-perceived handicap associated with dysphonia. Objectives: To test the psychometric properties of the Spanish version of the VHI-30 (Voice Handicap Index) and its shortened version VHI-10. Subjects and method: The original VHI-30 was translated into Spanish and was completed by 232 dysphonic patients and 38 non-dysphonic individuals. Prospective instrument validation was performed. Results: Results showed high test-retest reliability, and high item-total correlation for both Spanish VHI-30 and VHI-10. Internal consistency demonstrated a Cronbach’s alpha of 0.93 and 0.86, respectively, and a significant correlation was found between the VHI scores and the patients’ self-rated dysphonic severity. Conclusions: The present study supports the use of Spanish versions of VHI-30 and VHI-10 because of their validity and reliability